Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress

Rhea-AI Summary

Ra Medical Systems (RMED) announced that four clinical abstracts supporting its VIVO™ technology were accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) in Barcelona from April 16-18, 2023. VIVO is a proprietary AI system that assists in identifying the origins of ventricular arrhythmias prior to ablation procedures. The full acceptance rate of abstracts highlights the positive impact of VIVO on ablation processes. Following the conference, Ra Medical plans to release detailed clinical data, marking a significant milestone towards gaining wider clinical acceptance.

Positive

• Four clinical abstracts accepted for presentation at EHRA 2023, indicating strong peer recognition.
• The 100% acceptance rate of abstracts is a rare achievement, reflecting the potential of VIVO in the field.
• VIVO technology has received FDA marketing clearance and a CE mark, expanding its market potential.

Negative

• None.

Four abstracts with clinical data supporting use of Catheter Precision’s VIVO™ technology accepted for presentation at leading electrophysiology conference

FORT MILL, S.C.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) being held April 16-18, 2023 in Barcelona. VIVO, developed by Ra Medical’s wholly owned subsidiary Catheter Precision, is a proprietary AI system used to non-invasively identify the origin of ventricular arrhythmias prior to an ablation procedure.

“It is highly gratifying to present clinical data to the many electrophysiology thought leaders at the largest European meeting solely focused on arrhythmia management and treatment,” said David Jenkins, Ra Medical Executive Chairman. “All four abstracts with VIVO clinical data submitted by leading physicians to the Congress were accepted for presentation following an extensive peer-review process. To have one-hundred percent acceptance of submitted abstracts is rare and I believe indicative of the positive impact VIVO is having on ventricular ablation procedures. We view this recognition as a major milestone in gaining clinical acceptance by both EP thought leaders and the larger medical community.”

Ra Medical plans to issue a press release with clinical data from the abstract following presentations at EHRA 2023.

About EHRA
EHRA is a branch of the European Society of Cardiology (ESC). The European Heart Rhythm Association (EHRA) is the leading network of European Cardiac Rhythm Management with more than 4,100 members around the globe, including physicians, arrhythmia experts, electrophysiologists, nurses and allied professionals. The EHRA Congress brings together industry professionals to learn, discover and educate them on new and innovative technologies that impact arrhythmia treatment.

About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems
Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

VIVO Indications for Use
VIVO is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.

VIVO is intended to be used as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias.

Cautionary Note Regarding Forward-Looking Statements
This communication may contain forward-looking statements. Any forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by any forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can also be accessed on the Company’s Investor Relations page at https://ir.ramed.com/ by clicking on the link titled “SEC Filings.”

Any forward-looking statements included in this communication are made only as of the date hereof. The Company and Catheter assume no obligation and do not intend to update these forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005165/en/

At the Company

David Jenkins

973-691-2000

mhuck@catheterprecision.com



Investors

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: Ra Medical Systems, Inc.

FAQ

What is the purpose of Ra Medical's VIVO technology?

VIVO technology is designed to non-invasively identify the origin of ventricular arrhythmias prior to ablation procedures.

When and where will the EHRA 2023 Congress take place?

EHRA 2023 will be held in Barcelona from April 16-18, 2023.

What does the acceptance of abstracts at EHRA 2023 signify for RMED?

The acceptance signifies strong peer recognition and a potential positive impact of VIVO on ventricular ablation procedures.

What are the next steps for RMED following the EHRA Congress?

Ra Medical plans to release clinical data from the accepted abstracts after the presentations.

What regulatory clearances does VIVO technology currently have?

VIVO has received marketing clearance from the U.S. FDA and has the CE mark.